Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

Enzalutamide Prolongs Survival in Hormone-Resistant Prostate Cancer: Does It Also Help Bone Problems and Pain?

Enzalutamide Prolongs Survival in Hormone-Resistant Prostate Cancer: Does It Also Help Bone Problems and Pain?

A study observed that, in hormone-resistant prostate cancer, enzalutamide not only prolonged survival but also improved quality of life and delayed or even prevented some bone-related problems.

Prostate cancer is the most common cancer in men after skin cancer. Although treatment varies by stage, the conventional treatment for advanced (metastatic) prostate cancer suppresses androgens (male hormones), which are known to contribute to cancer development. This is hormonal therapy. The initial response is generally very good, but genetic alterations at the sites where androgens bind eventually lead to resistance to androgen suppression. From that point onward, the main goals are to prolong life and improve quality of life as much as possible. Traditionally, these patients first receive the chemotherapy drug docetaxel, which provides some survival benefit. However, no standard treatment approach has yet been established for disease that does not respond to docetaxel or stops responding after a period of time. Several treatments are being investigated for use at this stage (sipuleucel-T, abiraterone acetate, enzalutamide, cabazitaxel, and radium-223). One is enzalutamide.

Enzalutamide works by blocking the sites (receptors) where androgens bind and exert the effects that contribute to prostate cancer development. Clinical studies have shown that enzalutamide prolongs survival to some extent in these patients. However, advanced prostate cancer frequently spreads to the bones, causing serious bone problems and pain. Improving quality of life should therefore be a priority alongside prolonging survival. Clinical studies have shown substantial benefits of zoledronic acid and denosumab for bone-related problems, but no effect on survival has been established. A recent study marked an important development by finding that enzalutamide both prolonged survival and improved quality of life in these patients.

The study included approximately 1200 patients with hormone-resistant prostate cancer who had stopped responding to docetaxel. Some received enzalutamide regularly each day, while the other group did not, and their disease course was monitored. Bone problems developed and progressed later in the enzalutamide group, and pain was also less severe.

In conclusion, according to this study, enzalutamide has positive effects on quality of life in addition to prolonging survival, and it delays and prevents bone-related problems to some extent. Naturally, future studies will aim to resolve these problems completely rather than merely to some extent, and combinations of tumor-targeted and bone-targeted agents will be tested. Enzalutamide's effects make it a candidate for inclusion in these combinations.

Sources

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

Enzalutamide Prolongs Survival in Hormone-Resistant Prostate Cancer: Does It Also Help Bone Problems and Pain?

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy